Capsid inhibitors for the treatment of HIV

1. A compound of Formula I,

or a pharmaceutically acceptable salt thereof,

wherein

R 2 and R 3 are each independently H or C 1-3 alkyl;

each R 5 is halogen which may be the same or different;

R 1 is H, —CN, halogen, C 1-6 alkyl, C 3-7 monocyclic cycloalkyl, —C(O)NR 6 R 6 , —NR 6 R 6 , —NR 7 C(O)R 8 , or —C(O)R 8 , wherein the C 1-6 alkyl and C 3-7 monocyclic cycloalkyl are each optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy;

Ring B, together with the two carbons to which it is attached, forms a C 3-7 monocyclic cycloalkyl, 5-9 membered fused or bridged bicyclic cycloalkyl, 3-4 membered monocyclic heterocyclyl, 5-7 membered monocyclic heterocyclyl, or 5-9 membered fused or bridged bicyclic heterocyclyl,

wherein the C 3-7 monocyclic cycloalkyl, 5-9 membered fused or bridged bicyclic cycloalkyl, 3-7 membered monocyclic heterocyclyl, and 5-9 membered fused or bridged bicyclic heterocyclyl are each optionally substituted with 1-5 R 16 groups,

wherein the 3-4 membered monocyclic heterocyclyl has 1-2 ring heteroatoms independently selected from N, O, and S, and

wherein the 5-7 membered monocyclic heterocyclyl and 5-9 membered fused or bridged bicyclic heterocyclyl each have 1-3 ring heteroatoms independently selected from N, O, and S;

each R 16 is independently oxo, —OH, halogen, —CN, C 1-6 alkyl, C 1-4 alkoxy, C 3-7 monocyclic cycloalkyl, —C(O)NR 6 R 6 , —NR 6 R 6 , —NR 6 C(O)R 8 , or —C(O)R 8 , wherein the C 1-6 alkyl and C 3-7 monocyclic cycloalkyl are each optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy;

R 4 is a phenyl, 5-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 9-12 membered fused or bridged tricyclic heterocyclyl, or 9-12 membered fused tricyclic heteroaryl,

wherein the phenyl, 5-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 9-12 membered fused or bridged tricyclic heterocyclyl, and 9-12 membered fused tricyclic heteroaryl are each optionally substituted with 1-3 R 4a groups, and

wherein the 5-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 9-12 membered fused or bridged tricyclic heterocyclyl, and 9-12 membered fused tricyclic heteroaryl each have 1-3 ring heteroatoms independently selected from N, O, and S;

each R 4a is independently oxo, —OH, halogen, —CN, C 1-6 alkyl, C 1-6 alkoxy, —NR 6 R 6 , —NR 7 S(O) 2 R 9 , —NR 7 S(O) 2 NR 6 R 6 , —NR 7 C(O)R 8 , —NRC(O)R 10 NR 6 R 6 , —NR 7 C(O)NR 6 R 6 , or —C(O)NR 6 R 6 , wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy, or

two R 4a of the 1-3 R 4a groups are attached to the same carbon and the two R 4a , together with the carbon to which they are attached, form a C 3-7 monocyclic cycloalkyl;

each R 6 is independently H, C 1-8 alkyl, C 3-7 monocyclic cycloalkyl, or 4-6 membered monocyclic heterocyclyl having 1-3 ring heteroatoms independently selected from N, O, and S,

wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy, and

wherein the C 3-7 monocyclic cycloalkyl and 4-6 membered monocyclic heterocyclyl having 1-3 ring heteroatoms independently selected from N, O, and S are each optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, C 1-4 alkyl, and Ci-4 alkoxy; or

both R 6 , together with the nitrogen to which they are attached, form a 4-6 membered monocyclic heterocyclyl having 1-3 ring heteroatoms independently selected from N, O, and S;

each R 7 is independently H or C 1-8 alkyl which may be the same or different, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy;

each R 8 is independently —OH, C 1-8 alkyl, C 1-8 alkoxy, C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, or 4-6 membered monocyclic heteroaryl,

wherein the C 1-6 alkyl and C 1-6 alkoxy are each optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy,

wherein the C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, and 4-6 membered monocyclic heteroaryl are each optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, C 1-4 alkyl, and C 1-4 alkoxy, and

wherein the 4-6 membered monocyclic heterocyclyl and 4-6 membered monocyclic heteroaryl each have 1-3 ring heteroatoms independently selected from N, O, and S;

each R 9 is independently C 1-8 alkyl, C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, or 5-6 membered monocyclic heteroaryl,

wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy,

wherein the C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl are each optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, C 1-4 alkyl, and C 1-4 alkoxy, and

wherein the 4-6 membered monocyclic heterocyclyl and 5-6 membered monocyclic heteroaryl each have 1-3 ring heteroatoms independently selected from N, O, and S;

each R 10 is C 1-4 alkylene, which may be the same or different;

Ring A, together with the two carbons to which it is attached, forms a 5-6 membered monocyclic heterocyclyl or 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heterocyclyl and 5-6 membered monocyclic heteroaryl are each substituted with one Z group and each have 1-3 ring heteroatoms independently selected from N, O, and S;

Z is oxo, —OH, —CN, —NR 11 R 12 , C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, 8-10 membered fused or bridged bicyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl, 8-10 membered fused or bridged bicyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl are each optionally substituted with 1-3 R 13 groups and each have 1-3 ring heteroatoms independently selected from N, O, and S; and wherein the C 3-7 monocyclic cycloalkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy;

wherein one of R 11 and R 12 is H or C 1-8 alkyl and the other of R 11 and R 12 is C 1-6 alkyl, C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

wherein each C 1-6 alkyl is substituted with 1-3 R 17 groups,

wherein the C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl are each optionally substituted with 1-3 groups independently selected from oxo, —OH, halogen, —CN, C 1-4 alkyl, and C 1-4 alkoxy, and

wherein the 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl each have 1-3 ring heteroatoms independently selected from N, O, and S,

each R 17 is independently —OH, halogen, —CN, C 1-4 alkoxy, —NR 6 R 6 , C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl,

wherein the C 1-4 alkoxy, C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl are each optionally substituted with 1-3 groups independently selected from oxo, —OH, halogen, —CN, C 1-4 alkyl, and C 1-4 alkoxy, and

wherein the 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl each have 1-3 ring heteroatoms independently selected from N, O, and S;

each R 13 is independently oxo, —OH, halogen, —CN, C 1-4 alkyl, C 1-4 alkoxy, —NR 6 R 6 , —C(O)R 10 NR 6 R 6 , —C(O)NR 6 R 6 , —C(O)R 8 , C 6-10 monocyclic or fused bicyclic aryl, 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

wherein the C 6-10 monocyclic or fused bicyclic aryl, 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl are each optionally substituted with 1-3 R 14 groups, and

wherein the 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl each have 1-3 ring heteroatoms independently selected from N, O, and S;

each R 14 is independently halogen, C 1-4 alkyl, —C(O)R 8 , 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl,

wherein the C 1-4 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, CN, and C 1-4 alkoxy, and

wherein the 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl are each optionally substituted with C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted with —OR 10 Si(R 15 ) 3 ;

wherein the 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl each have 1-3 ring heteroatoms independently selected from N, O, and S;

each R 15 is independently C 1-3 alkyl, which may be the same or different; and

n is 0, 1, 2, or 3.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 2 and R 3 are each independently H or C 1-3 alkyl;

each R 5 is halogen which may be the same or different;

R 1 is H, —CN, halogen, C 1-6 alkyl, or C 3-7 monocyclic cycloalkyl, wherein the C 1-6 alkyl and C 3-7 monocyclic cycloalkyl are each optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy;

Ring B, together with the two carbons to which it is attached, forms a C 3-7 monocyclic cycloalkyl or 5-9 membered fused or bridged bicyclic cycloalkyl,

wherein the C 3-7 monocyclic cycloalkyl and 5-9 membered fused or bridged bicyclic cycloalkyl are each optionally substituted with 1-5 R 16a groups;

each R 16a is independently —OH, halogen, —CN, C 1-6 alkyl, C 1-4 alkoxy, and C 3-7 monocyclic cycloalkyl, wherein the C 1-6 alkyl and C 3-7 monocyclic cycloalkyl are each optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy;

R 4 is a phenyl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 9-12 membered fused or bridged tricyclic heterocyclyl,

wherein the phenyl, 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 9-12 membered fused or bridged tricyclic heterocyclyl are each optionally substituted with 1-3 R 4a groups, and

wherein the 8-10 membered fused or bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 9-12 membered fused or bridged tricyclic heterocyclyl each have 1-3 ring heteroatoms independently selected from N, O, and S;

each R 4a is independently oxo, —OH, halogen, —CN, C 1-6 alkyl, C 1-6 alkoxy, —NR 6 R 6 , —NR 7 S(O) 2 R 9 , or —C(O)NR 6 R 6 , wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy, or

two R 4a of the 1-3 R 4a groups are attached to the same carbon and the two R 4a , together with the carbon to which they are attached, form a C 3-7 monocyclic cycloalkyl;

each R 6 is independently H, C 1-8 alkyl, or C 3-7 monocyclic cycloalkyl,

wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy, and

wherein the C 3-7 monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, C 1-4 alkyl, and C 1-4 alkoxy;

each R 7 is independently H or C 1-8 alkyl which may be the same or different, wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy;

each R 8 is independently —OH, C 1-8 alkyl, or C 1-8 alkoxy;

each R 9 is independently C 1-6 alkyl or C 3-7 monocyclic cycloalkyl

wherein the C 1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy, and

wherein the C 3-7 monocyclic cycloalkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, —CN, C 1-4 alkyl, and C 1-4 alkoxy;

each R 10 is C 1-4 alkylene, which may be the same or different;

Ring A, together with the two carbons to which it is attached, forms a 5-6 membered monocyclic heterocyclyl or 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heterocyclyl and 5-6 membered monocyclic heteroaryl are each substituted with one Z group and each have 1-3 ring heteroatoms independently selected from N, O, and S;

Z is oxo, —OH, —CN, —NR 11 R 12 , C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, 8-10 membered fused or bridged bicyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl, 8-10 membered fused or bridged bicyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl are each optionally substituted with 1-3 R 13 groups and each have 1-3 ring heteroatoms independently selected from N, O, and S; and wherein the C 3-7 monocyclic cycloalkyl is optionally substituted with 1-2 groups independently selected from —OH, halogen, —CN, and C 1-4 alkoxy;

wherein one of R 11 and R 12 is H or C 1-6 alkyl and the other of R 11 and R 12 is C 1-6 alkyl, C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, or 5-6 membered monocyclic heteroaryl,

wherein each C 1-6 alkyl is substituted with 1-3 R 17a groups;

wherein the C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl are each optionally substituted with 1-3 groups independently selected from oxo, —OH, halogen, —CN, C 1-4 alkyl, and C 1-4 alkoxy, and

wherein the 4-6 membered monocyclic heterocyclyl and 5-6 membered monocyclic heteroaryl each have 1-3 ring heteroatoms independently selected from N, O, and S, each R 17a is independently —OH, halogen, —CN, C 1-4 alkoxy, —NR 6 R 6 , C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl,

wherein the C 1-4 alkoxy, C 3-7 monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, and 5-6 membered monocyclic heteroaryl are each optionally substituted with 1-3 groups independently selected from oxo, —OH, halogen, —CN, C 1-4 alkyl, and C 1-4 alkoxy, and

wherein the 4-6 membered monocyclic heterocyclyl and 5-6 membered monocyclic heteroaryl each have 1-3 ring heteroatoms independently selected from N, O, and S;

each R 13 is independently oxo, —OH, halogen, —CN, C 1-4 alkyl, C 1-4 alkoxy, —NR 6 R 6 , —C(O)R 10 NR 6 R 6 , —C(O)NR 6 R 6 , —C(O)R 8 , C 6-10 monocyclic or fused bicyclic aryl, 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, or 8-10 membered fused bicyclic heteroaryl,

wherein the C 6-10 monocyclic or fused bicyclic aryl, 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, and 8-10 membered fused bicyclic heteroaryl are each optionally substituted with 1-3 R 14 groups, and

wherein the 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, and 8-10 membered fused bicyclic heteroaryl each have 1-3 ring heteroatoms independently selected from N, O, and S;

each R 14 is independently halogen, C 1-4 alkyl, —C(O)R 8 , or 5-6 membered monocyclic heteroaryl having 1-3 ring heteroatoms independently selected from N, O, and S,

wherein the C 1-4 alkyl is optionally substituted with 1-3 groups independently selected from —OH, halogen, CN, and C 1-4 alkoxy, and

wherein the 5-6 membered monocyclic heteroaryl having 1-3 ring heteroatoms independently selected from N, O, and S is optionally substituted with C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted with —OR 10 Si(R 15 ) 3 ;

each R 15 is independently C 1-3 alkyl, which may be the same or different; and

n is 0, 1, 2, or 3.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring B is cyclohexyl, tetrahydropyranyl,

each of which is optionally substituted with 1-4 groups independently selected from oxo, —OH, halogen, —CN, C 1-6 alkyl, C 1-4 alkoxy, C 3-7 monocyclic cycloalkyl, —C(O)NR 6 R 6 , —NR 6 R 6 , —NR 6 C(O)R 8 , and —C(O)R 8 ; and

R 1 is C 1-4 alkyl optionally substituted with 1-3 halogens.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

is:

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is

each of which is optionally substituted with 1-3 R 4a groups.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 optionally substituted with 1-3 R 4a groups is:

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ring A, together with the two carbons to which it is attached, forms a 5-6 membered monocyclic heterocyclyl or 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heterocyclyl and 5-6 membered monocyclic heteroaryl are each substituted with one Z group and each have 1-3 ring heteroatoms independently selected from N, O, and S, wherein one or two ring heteroatoms is a nitrogen.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

is:

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is:

—NR 11 R 12 , wherein NR 11 R 12 is

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is

wherein

Ring Z a is a 4-6 membered monocyclic heterocyclyl, 8-10 membered fused or bridged bicyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl, wherein the 4-6 membered monocyclic heterocyclyl, 8-10 membered fused or bridged bicyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl each have one ring heteroatom that is nitrogen and each optionally have 1-2 additional ring heteroatoms independently selected from N, O, and S, and

Ring Z a is optionally substituted with 1-3 R 13 groups.

11. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein Ring Z a is

each of which is optionally substituted with 1-3 R 13 groups, independently selected from oxo, —OH, halogen, —CN, C 1-4 alkyl, C 1-4 alkoxy, —NR 6 R 6 , —C(O)R 10 NR 6 R 6 , —C(O)NR 6 R 6 , —C(O)R 8 , C 6- monocyclic or fused bicyclic aryl, 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, and 8-10 membered fused bicyclic heteroaryl, wherein the C 6-10 monocyclic or fused bicyclic aryl is optionally substituted with 1-3 R 14 groups and wherein the 4-6 membered monocyclic heterocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused or bridged bicyclic heterocyclyl, and 8-10 membered fused bicyclic heteroaryl each have 1-3 ring heteroatoms independently selected from N, O, and S; and

wherein each R 14 is independently halogen, C 1-4 alkyl, or 5-6 membered monocyclic heteroaryl,

wherein the C 1-4 alkyl is optionally substituted with 1-3 halogens, and

wherein the 5-6 membered heteroaryl is optionally substituted with —CH 2 OCH 2 CH 2 Si(CH 3 ) 3 and has 1-3 ring heteroatoms independently selected from N, O, and S.

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 6 is independently H or C 1-4 alkyl and R 8 is C 1-5 alkoxy.

13. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

15. A method of treating or preventing a human immunodeficiency virus (HIV) infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , further comprising administering a therapeutically effective amount of one or more additional therapeutic agents, or a pharmaceutically acceptable salt thereof.